The Anti-Vaccine Movement: Where Are We Now?
Despite scientific evidence to the contrary, doubts about vaccine safety and efficacy have not only persisted, but escalated. Counteracting this wave of mistrust will require targeted tactics and networked, community involvement.
Nasal COVID-19 Vaccine Trial Opens
A Phase I clinical trial testing the safety of an experimental nasal vaccine, MPV/S-2P, that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States.
New Pneumococcal Vaccine CAPVAXIVE Approved by FDA
The U.S. Food and Drug Administration has approved CAPVAXIVE for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae in individuals 18 years of age and older.
Study Uses Flu Virus to Speed Up COVID-19 Antibodies
A new vaccine may help speed up the process of making antibodies against SARS-CoV-2 by using preexisting immunity to a separate virus (the influenza virus).
Study Will Test Vaccine That Kills Cancer Cells Without Side Effects
A new cancer vaccine designed to detect and fight cancer cells without traditional cancer treatment is entering Phase III clinical trials.
Study Shows Patients Vaccinated Against Ebola Are Half as Likely to Die Than Unvaccinated Patients
A new study showed patients with confirmed Ebola virus disease were half as likely to die if they were vaccinated against the virus than if they were not.
Study Shows Positive Results for mRNA-Based Combination Influenza and COVID-19 Vaccine
A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech’s mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
FDA Approves Vaccine for Meningococcal Disease in Adolescents
Pfizer’s PENBRAYA, a vaccine for meningococcal groups A, B, C, W and Y, has been approved by the U.S. Food and Drug Administration (FDA).
Fourth Dose of COVID-19 Vaccine Increases Protection in Rheumatic Disease Patients
A new study suggests that patients receiving disease-modifying antirheumatic drugs should receive a fourth dose of the mRNA vaccine to protect against COVID-19.
First Vaccine for Mosquito-Born Viral Disease Is Approved by FDA
The U.S. Food and Drug Administration has approved IXCHIQ, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
